Clinical Efficacy Of BioMin F, Colgate Sensitive Pro-Relief And Sensodyne Rapid Action Dentifrices In DH
Launched by DOW UNIVERSITY OF HEALTH SCIENCES · Jan 29, 2020
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
It is a randomized controlled clinical trial with non invasive topical intervention in 140 adult patients of 18 to 60 years age, that will be selected randomly after screening and diagnosis of dentin hypersensitivity, in dental Out Patient Department of Periodontology. Written informed consent will be obtained. Participants will be allocated randomly into four equal study arms for parallel treatment assignment with dentifrices named BioMin F, Colgate Sensitive Pro-Relief Trade Mark,Sensodyne rapid action Trade Mark and Colgate Total Trade Mark dentifrices. Colgate total Trade Mark dentifric...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with at least two teeth sensitive to cold, touch and air blow stimulus
- • Sensitive teeth anterior to molars either due to erosions or abrasions with or without associated gingival recession
- • Teeth with Linear Visual Analogue Scale (VAS) score of ≥ 4 and code 2 of Schiff Cold Air Sensitivity Scale on screening.
- Exclusion Criteria:
- • Subjects with worst pain response at 100mm on VAS.(Visual Analog Scale)
- • Teeth with orthodontic or prosthetic appliances, Caries, restorations or cracks
- • Localized or generalized gingivitis or pulpitis with heavy calculus
- • Periodontal surgery in the preceding three months
- • Patients using any desensitizing tooth paste or mouth wash up to six weeks before study and taking drugs like anti-inflammatory, sedatives, tranquilizers, analgesics in routine.
- • Pregnant or breastfeeding females.
About Dow University Of Health Sciences
Dow University of Health Sciences (DUHS) is a premier educational and research institution based in Karachi, Pakistan, dedicated to advancing healthcare through innovative research and clinical excellence. As a clinical trial sponsor, DUHS integrates cutting-edge scientific inquiry with practical applications, fostering a collaborative environment that promotes the development of new treatments and therapies. The institution is committed to upholding the highest ethical standards in research, ensuring participant safety, and contributing to the global body of medical knowledge. With a focus on interdisciplinary collaboration and community health impact, DUHS plays a pivotal role in enhancing the quality of healthcare both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Karachi, Sindh, Pakistan
Patients applied
Trial Officials
Syed Jaffar Abbas Zaidi
Study Director
Dow University of Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials